Karuna Therapeutics Sees Breakthrough In Schizophrenia Drug
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
Alzheimer’s mainly affects the elderly, who are eligible for Medicare, but people under 65 — even, rarely, as young as their 30s — also can get diagnosed. They are more likely to have commercial coverage.
Some doctors say the drug should be held for three weeks before sedation to accommodate the delayed emptying of the stomach, which can cause patients to inhale food and liquid into their lungs.